Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 15.

Stahel, R A; Weder, W; Felley-Bosco, E; Petrausch, U; Curioni-Fontecedro, A; Schmitt-Opitz, I; Peters, S (2015). Searching for targets for the systemic therapy of mesothelioma. Annals of Oncology, 26(8):1649-1660.

Echeverry, N; Ziltener, G; Barbone, D; Weder, W; Stahel, R A; Broaddus, V C; Felley-Bosco, E (2015). Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K/mTOR inhibitors. Cell Death and Disease, 6:e1757.

Otterstrom, C; Soltermann, A; Opitz, I; Felley-Bosco, E; Weder, W; Stahel, R A; Triponez, F; Robert, J H; Serre-Beinier, V (2014). CD74: a new prognostic factor for patients with malignant pleural mesothelioma. British Journal of Cancer, 110(8):2040-2046.

Fischer, B; Frei, C; Moura, U; Stahel, R; Felley-Bosco, E (2012). Inhibition of phosphoinositide-3 kinase pathway down regulates ABCG2 function and sensitizes malignant pleural mesothelioma to chemotherapy. Lung Cancer, 78(1):23-29.

Shi, Y; Felley-Bosco, E; Marti, T M; Stahel, R A (2012). Differential effects of lovastatin on cisplatin responses in normal human mesothelial cells versus cancer cells: implication for therapy. PLoS ONE, 7(9):e45354.

Ziegler, A; Cerciello, F; Bigosch, C; Bausch-Fluck, D; Felley-Bosco, E; Ossola, R; Soltermann, A; Stahel, R A; Wollscheid, B (2012). Proteomic surfaceome analysis of mesothelioma. Lung Cancer, 75(2):189-196.

Felley-Bosco, E; Opitz, I; Soltermann, A; Thies, S; Weder, W; Stahel, R A (2011). Asbestos-induced tissue regeneration and malignant pleural mesothelioma: Insights from developmental studies. In: Berhardt, L V. Advances in Medicine and Biology. Volume 34. Hauppauge NY, USA: Nova Science Publishers, 131-153.

Shi, Y; Hollenstein, A; Felley-Bosco, E; Fraefel, C; Ackermann, M; Soltermann, A; Weder, W; Stahel, R A; Pruschy, M; Opitz, I (2011). Bioluminescence imaging for in vivo monitoring of local recurrence mesothelioma model. Lung Cancer, 71(3):370-371.

Sidi, R; Pasello, G; Opitz, I; Soltermann, A; Tutic, M; Rehrauer, H; Weder, W; Stahel, R A; Felley-Bosco, E (2011). Induction of senescence markers after neo-adjuvant chemotherapy of malignant pleural mesothelioma and association with clinical outcome: an exploratory analysis. European Journal of Cancer, 47(2):326-332.

Frei, C; Opitz, I; Soltermann, A; Fischer, B; Moura, U; Rehrauer, H; Weder, W; Stahel, R; Felley-Bosco, E (2011). Pleural mesothelioma side populations have a precursor phenotype. Carcinogenesis, 32(9):1324-1332.

Thurneysen, C; Opitz, I; Kurtz, S; Weder, W; Stahel, R A; Felley-Bosco, E (2009). Functional inactivation of NF2/merlin in human mesothelioma. Lung Cancer, 64(2):140-147.

Ampollini, L; Soltermann, A; Felley-Bosco, E; Lardinois, D; Arni, S; Speck, R F; Weder, W; Opitz, I (2009). Immuno-chemotherapy reduces recurrence of malignant pleural mesothelioma: an experimental setting. European Journal of Cardio-Thoracic Surgery, 35(3):457-462.

Stahel, R A; Felley-Bosco, E; Opitz, I; Weder, W (2009). Malignant pleural mesothelioma. Future Oncology, 5(3):391-402.

Stahel, R; Felley-Bosco, E; Opitz, I; Weder, W (2008). Mesothelioma. In: Hansen, H. Lung Cancer Therapy Annual 6. New York: Informa Healthcare USA, Inc., 205-222.

Diezi, J; Felley-Bosco, E (2008). Precis de toxicologie. Genève: Editions Médecine et Hygiène.

This list was generated on Sun Jun 16 22:06:13 2019 CEST.